Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 413Leukemia 346Leukemia, Myeloid, Acute 289Leukemia, Lymphocytic, Chronic, B-Cell 286Lymphoma 217Myelodysplastic Syndromes 207Lymphoma, Non-Hodgkin 196Burkitt Lymphoma 160Lymphoma, Follicular 149Lymphoma, Mantle-Cell 136Lymphoma, Large B-Cell, Diffuse 135Hodgkin Disease 131Multiple Myeloma 120Lymphoma, B-Cell, Marginal Zone 118Lymphoma, Large-Cell, Immunoblastic 95Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Hematologic Neoplasms 87Myeloproliferative Disorders 85Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78Recurrence 72Congenital Abnormalities 68Blast Crisis 64Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 63Graft vs Host Disease 62Neoplasms, Plasma Cell 61Anemia, Refractory, with Excess of Blasts 60Primary Myelofibrosis 59Dendritic Cell Sarcoma, Interdigitating 59

Interventions

Nivolumab 2prednylidene 1peginterferon alfa-2b 1dolutegravir 1deltacortene 1Zidovudine 1Vincristine 1Valproic Acid 1Tenofovir 1Specimen Handling 1Prednisone 1Pharmacogenomic Testing 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferon alpha-2 1Etoposide 1Doxorubicin 1Daclizumab 1Cyclophosphamide 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HTLV-I Infections × Cyclophosphamide × Other hematologic neoplasm × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡